A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

Main Inclusion Criteria:

   1. Women or men 18 to 75 years of age

   2. Greater than 1 year history of episodic, migraine (with or without aura) with onset
   prior to 50 years of age.

   3. Migraine history during the prior 6 months must include:

      1. at least 2 migraines per month

      2. no more than 8 migraines per month

      3. no more than 15 headache days per month

   4. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy
   and use an acceptable double-barrier method of birth control during the trial.

   5. Willing and able to treat a minimum of 2 migraines per month with study medication and
   consistently complete eDiary for up to 12 months.

Main Exclusion Criteria:

   1. Contraindication to triptans

   2. Use of selective serotonin reuptake inhibitors (drugs like Prozac®) or serotonin or
   norepinephrine reuptake inhibitors (drugs like Effexor®) or anti-coagulants (drugs
   like Coumadin®)

   3. Known allergy or sensitivity to zolmitriptan or its derivatives or formulations

   4. Known allergy or sensitivity to adhesives and/or titanium

   5. Women who are pregnant, breast-feeding or plan a pregnancy during this study

   6. Three or more of the following cardiovascular risk factors:

      - Current tobacco use

      - Hypertension or receiving anti-hypertensive medication for hypertension

      - Hyperlipidemia or on prescribed anti-cholesterol treatment

      - Family history of premature coronary artery disease

      - Diabetes mellitus

   7. History or current abuse or dependence on alcohol or drugs